Janus kinase inhibitors in autoimmune diseases

Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of the rheumatic diseases Vol. 72 Suppl 2; p. ii111
Main Authors:	O'Shea, John J, Kontzias, Apostolos, Yamaoka, Kunihiro, Tanaka, Yoshiya, Laurence, Arian
Format:	Journal Article
Language:	English
Published:	England 01-04-2013
Subjects:	Arthritis, Rheumatoid - drug therapy Autoimmune Diseases - drug therapy Cytokines - physiology Humans Janus Kinases - antagonists & inhibitors Molecular Targeted Therapy Signal Transduction
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to consider this new category of drugs and reflect on their potential roles, present and future, in the treatment of RA and related disorders.
ISSN:	1468-2060
DOI:	10.1136/annrheumdis-2012-202576